Fiera Capital Corp Mirati Therapeutics, Inc. Transaction History

Fiera Capital Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$27.8 - $45.35 $9.64 Million - $15.7 Million	346,803 Added 50.11%	1,038,836 $45.3 Million
Q2 2023 Aug 09, 2023	SELL	$36.13 - $49.49 $632,058 - $865,778	-17,494 Reduced 2.47%	692,033 $25 Million
Q1 2023 Apr 26, 2023	BUY	$36.54 - $54.26 $616,429 - $915,366	16,870 Added 2.44%	709,527 $26.4 Million
Q4 2022 Feb 08, 2023	BUY	$41.27 - $98.62 $6.57 Million - $15.7 Million	159,307 Added 29.87%	692,657 $31.4 Million
Q3 2022 Nov 03, 2022	SELL	$59.5 - $86.7 $400,732 - $583,924	-6,735 Reduced 1.25%	533,350 $37.2 Million

Q2 2022 Aug 10, 2022	BUY	$39.16 - $88.71 $10.2 Million - $23 Million	259,368 Added 92.39%	540,085 $36.3 Million
Q1 2022 May 09, 2022	BUY	$75.82 - $150.97 $21.3 Million - $42.4 Million	280,717 New	280,717 $23.1 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Fiera Capital Corp with notifications on news.